Drug profile

The FDA adverse-event record for Milbemycin Oxime And Lufenuron

26 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin Oxime And Lufenuron. See the species affected, top reactions, and outcomes below.

26
adverse-event reports
7.7%
death-coded share
Dog
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26
Total Reports
2
Deaths Reported
7.7%
Death Rate

Active Ingredients

Milbemycin Oxime And Lufenuron

Administration Routes

OralUnknown

Species Affected

Dog 26

Most Affected Breeds

Retriever - Labrador 5
Terrier - Boston 2
Greyhound 1
Beagle 1
Pointing Dog - German Short-haired 1
Mountain Dog - Bernese 1
Terrier (unspecified) 1
Poodle - Miniature 1
Weimaraner 1
Hound (unspecified) 1

Most Reported Reactions

Vomiting 5
Facial swelling (see also 'Skin') 3
Phlebitis 2
Pain NOS 2
Death by euthanasia 2
Decreased appetite 2
Loose stool 2
Lethargy (see also Central nervous system depression in Neurological) 2
Pacing 2
Panting 2
Incorrect route of drug administration 2
Seizure NOS 2

Outcome Breakdown

Recovered/Normal
12 (46.2%)
Outcome Unknown
9 (34.6%)
Ongoing
3 (11.5%)
Euthanized
2 (7.7%)

Milbemycin Oxime And Lufenuron Adverse Event Insights

26 reports name Milbemycin Oxime And Lufenuron; 2 recorded a death outcome (7.7% of reported events, not a population-level mortality rate). Active ingredient: Milbemycin Oxime And Lufenuron. Administration routes: Oral, Unknown.

By species: Dog (26 reports). By breed: Retriever - Labrador (5), Terrier - Boston (2), Greyhound (1).

Leading clinical signs: Vomiting (5), Facial swelling (see also 'Skin') (3), Phlebitis (2), Pain NOS (2). Outcome, 26 coded reports: Recovered/Normal leads at 46.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.